Abstract
Background and Purpose
Heat‐sensitive transient receptor potential vanilloid (TRPV) channels are expressed in various epithelial tissues regulating, among else, barrier functions. Their expression is well established in the distal nephron; however, we have no data about their presence in podocytes. As podocytes are indispensable in the formation of the glomerular filtration barrier, we investigated the presence and function of Ca2+‐permeable TRPV1–4 channels in human podocyte cultures.
Experimental Approach
Expression of TRPV1–4 channels was investigated at protein (immunocytochemistry, Western blot) and mRNA (Q‐PCR) level in a conditionally immortalized human podocyte cell line. Channel function was assessed by measuring intracellular Ca2+ concentration using Flou‐4 Ca2+‐indicator dye and patch clamp electrophysiology upon applying various activators and inhibitors.
Key Results
Thermosensitive TRP channels were expressed in podocytes. The TRPV1‐specific agonists capsaicin and resiniferatoxin did not affect the intracellular Ca2+ concentration. Cannabidiol, an activator of TRPV2 and TRPV4 channels, induced moderate Ca2+‐influxes, inhibited by both tranilast and HC067047, blockers of TRPV2 and TRPV4 channels respectively. The TRPV4‐specific agonists GSK1016790A and 4α‐phorbol 12,13‐didecanoate induced robust Ca2+‐signals which were abolished by HC067047. Non‐specific agonists of TRPV3 channels induced marked Ca2+ transients. However, TRPV3 channel blockers, ruthenium red and isopentenyl diphosphate only partly inhibited the responses and TRPV3 silencing was ineffective suggesting remarkable off‐target effects of the compounds.
Conclusion and Implications
Our results indicate the functional presence of TRPV4 and other thermosensitive TRPV channels in human podocytes and raise the possibility of their involvement in the regulation of glomerular filtration barrier.
Abbreviations
- 2‐APB
2‐aminoethoxydiphenyl borate
- 4α‐PDD
4α‐phorbol 12,13‐didecanoate
- CBD
cannabidiol
- FSGS
focal segmental glomerulosclerosis
- IP3
inositol trisphosphate
- IPP
isopentenyl diphosphate
- PPIA
peptidylprolyl isomerase A
- Q‐PCR
quantitative real‐time PCR
Introduction
Among voltage gated ion channels, the transient receptor potential (TRP) ion channels form a heterogeneous group with diverse functions. They are sensitive to various physical stimuli, like osmotic challenges, mechanical stimulation, changes of membrane potential or environmental temperature. Therefore, they are generally considered as multimodal cellular sensors. Moreover, TRP channels possess marked chemosensitivity, as well. They can be activated or inhibited by several endogenous or exogenous chemical ligands opening a huge field for potential pharmacological interventions (Nilius and Szallasi, 2014). Among TRP channels, the thermosensitive members are the most pursued drug targets especially because of their vital role in several sensory functions (Moran et al., 2011). However, thermoTRPs, especially the heat‐sensitive members of the TRP vanilloid (TRPV) subfamily, play an emerging role in epithelial biology and barrier functions, as well (Moran et al., 2011; Nilius and Szallasi, 2014). They are widely expressed in the outer and inner linings of the human body, in the skin (Tóth et al., 2014), airway epithelia (Grace et al., 2014), endothelium (Earley and Brayden, 2015) or reabsorbing epithelium of kidney tubules (Kassmann et al., 2013).
Several TRP channels are expressed along the nephron playing important (patho)physiological roles in kidney functions (Woudenberg‐Vrenken et al., 2009). TRPV5, TRPV6 and TRPM6 channels, expressed in the apical membrane of distal tubule epithelium, play an essential role in ion homeostasis via ensuring physiological reabsorption of Ca2+ and Mg2+ respectively (Dimke et al., 2011). Mutations in the TRPP 1/2 complex serve as etiological factors in the development of polycystic kidney disease (Retailleau and Duprat, 2014; Tóth and Nilius, 2015). The TRPC6 channel regulates podocyte function influencing the integrity of the glomerular filtration barrier and playing an etiological role in different proteinuric diseases, including familial focal segmental glomerulosclerosis (FSGS) (Dryer and Reiser, 2010; Tóth and Nilius, 2015).
Regarding the heat‐sensitive TRPV channels, TRPV4 is expressed in various segments of the urogenital tract, involving distal tubules of the kidney, and it plays an important role in cell junction and barrier formation (Janssen et al., 2016). The presence of TRPV1 channels was also shown in the tubules of the renal cortex and medulla as well as in the wall of the renal pelvis (Feng et al., 2008; Kassmann et al., 2013). Moreover, both TRPV1 and TRPV4 channels can influence endothelial barrier functions (Alvarez et al., 2006; Yang et al., 2010) which can affect the vascular side of the glomerular filtration barrier. However, we do not have any data about the expression of these channels in the other component of the glomerular filtration barrier, that is, the podocytes of Bowman's capsule. Therefore, in the current study, we aimed at investigating the molecular expression and functionality of heat‐sensitive TRPV1–4 channels in human podocytes using a conditionally immortalized human podocyte cell culture system.
Methods
Cell cultures
The human podocyte cell line provided by Prof. Hermann Pavenstädt (University Hospital of Münster, Münster, Germany) was established and cultured as described previously (Saleem et al., 2002; Ambrus et al., 2015). In brief, cells were cultured in ‘permissive’ condition in RPMI medium (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% fetal bovine serum (Invitrogen, Paisley, UK), 50 U·mL−1 penicillin, 50 μg·mL−1 streptomycin, 1.25 μg·mL−1 Fungizone (both from PPA Laboratories GmbH) and insulin‐transferrin‐selenium (1:100; Invitrogen) at 33°C to maintain proliferation. Differentiation was induced by switching to ‘non‐permissive’ condition transferring cells to 37°C and kept in culture for 7 days. The process of differentiation was evaluated using Western blotting and immunocytochemistry by determining the expression of the podocyte‐specific marker podocin and the differentiation marker synaptopodin as shown in our previous work (Ambrus et al., 2015). HEK293T cells were cultured in DMEM medium (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (Invitrogen), 50 U·mL−1 penicillin, 50 μg·mL−1 streptomycin, 1.25 μg·mL−1 Fungizone (both from PPA Laboratories GmbH) and non‐essential aminoacids (Sigma‐Aldrich, St Louis, MO, USA).
Antibodies
The following primary antibodies were employed for immunocytochemistry: mouse anti‐human TRPV1, rabbit anti‐human TRPV4 (both from Novus Biologicals, Littleton, CO, USA), rabbit anti‐human TRPV2 and rabbit anti‐human TRPV3 (both from Abcam, Cambridge, UK). For Western blotting, we used goat anti‐human TRPV1 (Santa Cruz, Heidelberg, Germany), rabbit anti‐human TRPV3, rabbit anti‐human TRPV4 (Alomone Labs, Jerusalem, Israel), rabbit anti‐human TRPV2 and rabbit‐anti‐human β‐actin (ACTB) (Sigma‐Aldrich).
Immunocytochemistry
Human podocytes were cultured and differentiated on glass coverslips in six‐well plates, were fixed by 4% paraformaldehyde containing PBS (115 mM NaCl, 20 mM Na2PO4, pH 7.4; all from Sigma‐Aldrich) for 10 min at room temperature and were permeabilized by 0.3% Triton‐X‐100 (Sigma‐Aldrich) in PBS for 10 min. Following 30 min incubation in blocking solution (0.3% Triton‐X‐100 and 1% BSA containing PBS; both from Sigma‐Aldrich) at room temperature, cells were probed with the previously mentioned primary antibodies raised against human TRPV1 (1:50), TRPV4 (1:50), TRPV2 (1:100) and TRPV3 (1:100) overnight at 4°C. Following appropriate washing in PBS, coverslips were incubated with Alexa‐488®‐conjugated goat‐anti‐mouse and goat‐anti‐rabbit secondary antibodies (1:200, Invitrogen) for 1 h at room temperature. Nuclei were counterstained with DAPI (Vector Laboratories, Peterborough, UK). Negative control cells were stained omitting the primary antibodies. Visualization of the proteins was performed by using Zeiss LSM 510 Meta Confocal Microscope (Zeiss, Oberkochen, Germany).
Western blot
Cells were harvested and homogenized in protease inhibitor cocktail (1:100; Sigma‐Aldrich) containing detergent mixture (50 mM TRIS HCl, 150 mM NaCl, 1% Triton X‐100, 1% Igepal CA 630, 0.5% sodium deoxicholate; Sigma‐Aldrich). Protein concentrations were determined by using BCA reagent (Pierce, Rockford, IL, USA) and set to 0.5 μg·mL−1. Equal amount of protein samples (5 μg per well) were subjected to SDS‐PAGE (10% Mini Protean TGX gels, BioRad, Hercules, CA, USA) and transferred to nitrocellulose membranes, by using Trans‐Blot® Turbo™ Nitrocellulose Transfer Packs and Trans Blot Turbo System (both from BioRad). Membranes were probed with the corresponding primary antibodies overnight at 4°C. We applied anti‐human TRPV1, TRPV2, TRPV4 (1:100) and TRPV3 (1:200) antibodies, diluted in 5% milk containing PBS. As secondary antibodies, horseradish peroxidase‐conjugated rabbit anti‐goat and goat anti‐rabbit IgGs (1:1000, BioRad) were applied, and the immunoreactive bands were visualized by a SuperSignal West Pico Chemiluminescent Substrate‐Enhanced Chemiluminescence kit (Pierce) using Gel Logic 1500 Imaging System (Kodak, Tokyo, Japan). To assess equal amount of protein in the different samples, we used β‐actin as control, with rabbit anti‐human β‐actin antibody (1:1000, Sigma‐Aldrich).
Transient overexpression of human recombinant TRPV channels
To check the specificity of the antibodies used in Western blot experiments, we transiently overexpressed human recombinant TRPV1–4 proteins in HEK293T cells and subjected the cell lysates to Western blotting. HEK293T cells cultured in 96 mm Petri dishes were transfected at 50–60% confluency using TransIT‐293 Transfection Reagent (MirusBio, Madison, WI, USA). About 36 μL TransIT‐293 reagent and 12 μL DNA construct were gently mixed in 600 μL OptiMEM (LifeTechnologies) medium, incubated for approximately 20 min and added to the cell cultures drop by drop. Following an incubation for additional 48 h, cells were harvested and analysed by Western blotting, as described above. As DNA constructs, sequence of human TRPV1 was cloned in the pCAGGSM2‐IRES‐GFP‐R1R2 vector, and sequences of human TRPV2, TRPV3 and TRPV4 isoforms were cloned in the pCINeoIRES‐GFP vector. The constructs were provided by Prof. Thomas Voets (Laboratory of Ion Channel Research, KU Leuven, Leuven, Belgium).
Gene silencing by RNA interference (RNAi)
Human podocytes were seeded in small Petri dishes or in 96‐well black‐wall/clear‐bottom plates (Greiner Bio‐One, Kremsmuenster, Austria) suitable for fluorescent measurements in culture medium. After podocytes differentiation, medium was changed to fresh culture medium and cells were transfected with siRNA oligonucleotides targeting human TRPV3 (Stealth RNAi, Invitrogen, ID: HSS136315) using Lipofectamine™ RNAiMAX Transfection Reagent and serum‐free Optimem (both from Invitrogen). For controls, siRNA Negative Control Duplexes (scrambled RNA, Invitrogen) were employed. Forty‐eight hours after transfection, cells in Petri dishes were harvested to quantitatively evaluate the efficacy of siRNA‐driven silencing by Q‐PCR and fluorescent Ca‐measurements were performed on cells seeded in microplates.
Quantitative real‐time PCR (Q‐PCR)
To determine the quantitative expressions of various TRPs at the mRNA level, Q‐PCR was performed on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA) using the 5′ nuclease assay. Total RNA was isolated using TRIzol (Invitrogen) and reverse‐transcribed into cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and then amplified on a GeneAmp PCR System 2400 DNA Thermal Cycler (Applied Biosystems). PCR amplification was performed by using TaqMan primers and probes (assay ID‐s: Hs00218912_m1 for TRPV1, Hs00275032_m1 for TRPV2, Hs00376854_m1 for TRPV3 and Hs00222101_m1 for TRPV4; all from Applied Biosystems). As internal controls, transcripts of peptidylprolyl isomerase A (PPIA; assay ID: Hs99999904_m1), GAPDH (assay ID: Hs99999905_m1) and β‐actin (assay ID: Hs99999903_m1) were determined (all from Applied Biosystems). During the analysis, we used the geometric mean of the PPIA, GAPDH and β‐actin as reference value.
Fluorescent Ca2+ measurements
Fluorescent measurement of cytoplasmic Ca2+ concentration was performed according to our previously optimized protocol: human podocytes were seeded in 96‐well/clear‐bottom plates (Greiner Bio‐One) at a density of 20 000 cells per well in podocyte medium and cultured at ‘non‐permissive’ conditions for 7 days. On the 7th day, the cells were washed once with Hanks solution (‘normal buffer’: 136.8 mM NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 0.81 mM MgSO4, 1.26 mM CaCl2, 5.56 mM glucose, 4.17 mM NaHCO3, pH 7.2, all from Sigma‐Aldrich) containing 1% bovine serum albumin and 2.5 mM Probenecid (both from Sigma‐Aldrich) then loaded with 1 μM Fluo‐4 AM (Life Technologies Corporation, Carlsbad, CA, USA) dissolved in Hanks solution (100 μL per well) at 37°C for 30 min. The cells were washed three times with Ca2+‐containing (normal buffer) or Ca2+‐free (Ca2+‐free buffer) Hanks solution (100 μL per well). In the Ca2+‐free buffer, equimolar glucose substituted for CaCl2. The plates were then placed into a FlexStation 3 fluorescent microplate reader (Molecular Devices, Sunnyvale, CA, USA), and cytoplasmic Ca2+ concentration (reflected by fluorescence; λEX: 494 nm, λEM: 516 nm) was monitored during application of compounds in various concentrations. During the measurements, cells in a given well were exposed to only one given concentration of the agents. When applying antagonists, cells were pretreated for 30 min and the measurements were carried out in the continuous presence of fixed concentration of the applied antagonist. Experiments were performed in multiple wells, and cells in different wells were cultured, differentiated and treated individually and independently. Data are presented as F1/F0, where F0 is the average fluorescence of the baseline (before compound application) and F1 is the actual fluorescence. During data analysis, n represents individual, independently measured wells.
To investigate the effect of a heat pulse on intracellular Ca2+ concentration, podocytes were seeded and differentiated in 35 mm diameter Petri dishes and loaded with 1 μM Fluo‐4 AM (Life Technologies). Then, Petri dishes containing 300 μL ambient temperature normal buffer were placed on the stage of an Olympus IX83 inverted fluorescent microscope (Olympus, Tokyo, Japan), and Fluo‐4 loaded cells were imaged with constant settings in every 9 s, using the autofocus mode between each capturing. During measurement, 1 mL pre‐heated solution was pipetted into the Petri dishes. Images were captured using an Xcellence Pro live cell imaging system (Olympus) and analysed in Fiji app running ImageJ software (Schindelin et al., 2012, 2015).
Patch clamp recording
Podocytes were seeded in small Petri dishes and whole‐cell patch clamp measurements were made by using an Axopatch 1.D amplifier and Clampex 10.2 software (Molecular Devices) on the next day. To record GSK‐evoked transmembrane currents, experiments were performed in a bath solution containing 150 mM NaCl, 6 mM CsCl, 5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES and 10 mM glucose buffered to pH 7.4 (NaOH), whereas the pipette solution consisted of 100 mM aspartic acid, 20 mM CsCl, 1 mM MgCl2, 0.08 mM CaCl2, 4 mM Na2ATP, 10 mM EGTA, 10 mM HEPES and pH was set to 7.2 using CsOH resulted in approximately 100 mM Cs aspartate in the final pipette solution. The holding potential was 0 mV, and cells were ramped every 2 s from −120 to +100 mV over the course of 400 ms.
Curve fitting
Logistic dose–response curves were fitted using the equation y = A2 + (A1‐A2)/(1 + (x/x0)^p) where the calculated parameters are as follows: A1: initial value (ymin); A2: final value (ymax); x0: centre (EC50); and P is the calculated power. Fittings were carried out, and parameters were calculated using Origin 9.0 (OriginLab Corporation, Northampton, MA, USA).
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015). If not mentioned otherwise, data are presented as mean ± SEM. As the experiments were carried out on cell cultures using objective methods resulting in quantitative, interval scale numeric data which were analysed by properly chosen statistical methods, we discounted any influence of the experimenter's expectations on the results. Therefore, no randomization and blinding was performed. Normality of data was tested by Shapiro–Wilk test in each group. Means of multiple groups were compared by one‐way ANOVA. If F achieved P < 0.05, pairwise comparison was done by appropriate post hoc tests. Homogeneity of variances was tested by Levene's test. If no inhomogeneity was found, ANOVA was followed by either Dunnett or Bonferroni post hoc tests, as appropriate. In case of inhomogeneous variances, Dunnett's T3 test was performed. To compare means of two groups with data not passing normality, Mann–Whitney U‐test was performed. In every case, P < 0.05 was regarded as showing significant differences between group means. All statistical analysis was carried out using IBM SPSS Statistics 23.0 (IBM, Armonk, NY, USA).
Materials
Capsaicin, capsazepine, eugenol, carvacrol, thymol, 2‐aminoethoxydiphenyl borate (2‐APB), 4α‐phorbol 12,13‐didecanoate (4α‐PDD) and GSK1016790A were obtained from Sigma‐Aldrich. AMG 9810, cannabidiol (CBD) and HC067047 were purchased from Tocris Bioscience (Bristol, UK) and resiniferatoxin from Santa Cruz (Santa Cruz, CA, USA). Tranilast was bought from Cayman Chemical Company (Ann Arbor, MI, USA). Isopentenyl diphosphate (IPP) was from Echelon Biosciences (Salt Lake City, UT, USA). Ruthenium red was obtained from Research Biochemicals International (Natick, MA, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c).
Results
First, we investigated the molecular expression of heat‐sensitive TRPV1–4 channels in cultured, differentiated human podocytes. Immunocytochemical staining revealed a general expression of all the investigated proteins in differentiated human podocytes, although the staining for TRPV1 channels showed a relatively weaker signal compared to TRPV2–4 channels (Figure 1A). For Western blot, we have used selected antibodies of which specificity we have checked by probing human recombinant TRPV1–4 channels overexpressed in HEK‐derived (HEK293T) cell line (Supporting Information Figure S1). The selected antibodies detected all the investigated TRPV isoforms both in differentiated and non‐differentiated podocytes, although the molecular weight of the detected bands was not fully identical with the size of the bands detected in the recombinant cell line (Figure 1B). The podocytes‐specific TRPV1 and TRPV2 bands were detected at a minimal higher molecular weight. The specific antibody detected multiple bands of the recombinant TRPV3 channels among which only one (approximately 60 kDa) was detected in podocytes. Interestingly, the TRPV4‐specific antibody detected a very clear single band corresponding to the predicted molecular weight of the TRPV4 channel in HEK293T cells overexpressing the recombinant channel. However in podocytes, we could detect very intense signals but at definitely lower molecular weight. Nevertheless, each protein was detected both in differentiated and undifferentiated cells, as well. Generally, the intensity of all the TRPV1–4 immunoreactivity was found to be decreased in differentiated podocytes compared to undifferentiated cells. To further assess the quantitative expression of TRPV channels compared to each other, we studied the expression of specific TRPV transcripts by Q‐PCR. We found that the expression of TRPV1 and TRPV4 was relatively high, but TRPV2 and TRPV3 protein were expressed at relatively low levels (Figure 1C).
As the molecular expression studies revealed a general expression of heat‐sensitive TRPV channels, we investigated the functional responses for a thermal challenge applying a heat pulse by adding pre‐warmed buffer to differentiated podocyte cultures. Because the studied channels are Ca2+‐permeable, their activity was investigated by monitoring the intracellular Ca2+ concentration using the fluorescent Ca2+‐sensitive reporter dye Fluo‐4, upon heat stimulation. The majority of the cells reacted to the heat pulse with a transient elevation of the intracellular Ca2+ concentration (Figure 1D–F, Supporting Information Videos S1 and S2), a response which was not seen after applying ambient temperature as a stimulus (Figure 1F and Supporting Information Video S3). These results clearly indicated the presence of heat‐sensitive Ca2+ channels in differentiated human podocytes. However, the applied heat pulse protocol was not specific enough to identify the individual heat‐sensitive channels and discriminate between the contributions of the different TRPV isoforms which can exhibit partly overlapping temperature sensitivity in various conditions. Therefore, to judge the function of the individual TRPV isoforms, we used various pharmacological tools to activate these channels and assessed their specificity by applying specific antagonist pretreatments, if specific antagonists were available.
Capsaicin, a specific, potent activator of TRPV1 channels (Caterina et al., 1997), did not induce any remarkable alteration in the intracellular Ca2+ concentration of the podocytes up to 1 mM. The presence of the TRPV1‐specific antagonists, capsazepine or AMG 9810, did not influence the lack of the capsaicin effect (Figure 2A, B). Similarly, the ultrapotent TRPV1 channel agonist resiniferatoxin also failed to evoke any response (Figure 2C). These results suggested that TRPV1, in spite of the relatively high expression of the mRNA transcripts, does not form a functional channel in the cultures of differentiated human podocytes.
The phytocannabinoid CBD, an agonist of both TRPV2 (Qin et al., 2008) and TRPV4 channels (De Petrocellis et al., 2012), induced a moderate elevation of intracellular Ca2+ concentration when applied at ≥10 μM concentration (EC50 = 10.6 ± 1.3 μM – Figure 3.). This effect was mainly eliminated by omitting the Ca2+ from the extracellular solution suggesting that CBD activated Ca2+‐permeable ion channels in the plasma membrane. The presence of 75 μM tranilast (Nie et al., 1997), a potent ion channel inhibitor recently used to target TRPV2 channels (Hisanaga et al., 2009; Mihara et al., 2010; Perálvarez‐Marín et al., 2013), effectively inhibited the CBD‐induced Ca2+ signals suggesting the presence of functionally active TRPV2 channels. However, CBD was also reported as a weak agonist of TRPV4 channels (De Petrocellis et al., 2012). Therefore, we investigated the involvement of TRPV4 in the CBD‐induced Ca2+ signals, repeating the experiments in the presence of HC067047, a potent and selective blocker of TRPV4 channels (Everaerts et al., 2010). About 1 μM HC067047 inhibited the CBD‐induced Ca2+ responses approximately as effectively, as tranilast did (Figure 3.), further confirming our previous results that CBD can activate TRPV4 channels (Oláh et al., 2014) and suggesting the presence of functional TRPV4 channels in human podocytes.
To further dissect the functionality of TRPV4 channels, we investigated the effect of the hyper‐potent TRPV4 channel agonist, GSK1016790A (Thorneloe et al., 2008) on the intracellular Ca2+ concentration of podocytes. We found that GSK1016790A, applied at nM concentrations, induced a rapid and robust elevation of intracellular Ca2+ concentration which was strongly inhibited by the selective blocker of TRPV4 channels, HC067047 (EC50 values were 3.63 ± 0.33 and 57.07 ± 6.02 nM in the absence and presence of 1 μM HC067047 respectively; Figure 4A, B). Not only the peak but also the slope of the Ca2+‐transients was increased dose‐dependently by GSK1016790A in Ca2+ containing buffer, even after the saturation of the Ca2+ signals, clearly indicating higher open probability of TRPV4 channels located in the plasma membrane (Figure 4C, D). GSK1016790A elevated the intracellular Ca2+ even in the absence of extracellular Ca2+, although it was less potent (EC50 = 10.04 ± 0.72 nM) and definitely slower than in normal, Ca2+ buffer (Figure 4A–D), suggesting that functional TRPV4 channels are expressed on the intracellular Ca2+ stores, as well. However the much steeper rising phase in the presence of extracellular Ca2+ suggested that the majority of the channels are activated by the agonist in the plasma membrane (Figure 4D). The classical TRPV4 channel agonist 4α‐PDD (Watanabe et al., 2002) also raised the intracellular Ca2+ concentration (EC50 = 0.52 ± 0.06 μM), and its effect was also inhibited by HC067047, although 4α‐PDD was less effective than GSK1016790A (Figure 4E, F). 4α‐PDD‐evoked responses were abolished in the absence of extracellular Ca2+ suggesting again that the majority of the activated TRPV4 channels are located in the plasma membrane. This was also supported by whole‐cell patch clamp experiments in which we have detected strong GSK1016790A‐induced transmembrane currents whose biophysical characteristics corresponded to TRPV4 currents. Similarly to the Ca2+ signals, GSK1016790A‐induced transmembrane currents were also inhibited by HC067047 (Figure 4G, H).
As specific agonist and antagonists are not available commercially, the pharmacological identification and separation of TRPV3 channels is the most challenging among heat‐sensitive TRPV channels. Although they lack specificity, several herbal compounds, like eugenol, thymol or carvacrol, are reported as potent activators of TRPV3 channels (Xu et al., 2006; Vriens et al., 2008). Testing these compounds on differentiated human podocytes, we found a marked activation in the concentration range reported for effective activation of TRPV3 channels (Xu et al., 2006; Vriens et al., 2008), suggesting the presence of functional TRPV3 on human podocytes (Figure 5A, B.). However, the dose–response relationships were not saturated up to 1.5 mM and did not show sigmoid shape, suggesting that these compounds can activate other targets on podocytes, as well. In contrast, application of 2‐APB, a synthetic but also not specific activator of TRPV3 channels (Chung et al., 2004; Vriens et al., 2009), significantly elevated cytoplasmic Ca2+ concentration from extracellular source resulting in a sigmoidal dose–response relationship (EC50 = 499 ± 51.2 μM) (Figure 5C, D). Although the above compounds are effective activators of TRPV3 channels, all of them lack specificity and can affect cytoplasmic Ca2+ concentration via several other targets including other TRP channels, store operated Ca2+ entry or inositol trisphosphate (IP3) receptors. Selected concentrations of carvacrol, thymol and 2‐APB were only partially inhibited by the general, non‐specific TRP channel inhibitor ruthenium red (≤35% inhibition); likewise, the endogenous TRPV3 inhibitor IPP (Bang et al., 2011) partly inhibited only the 2‐APB induced Ca2+ transients (~23% inhibition) (Figure 5E). Transfection of the podocytes with siRNA targeting TRPV3 channels resulted in a marked decrease in the expression of the channel compared to the scrambled RNA transfected control cells (Figure 5F). Although the TRPV3 silencing was found effective, it did not influence the Ca2+ responses evoked by the agonists shown above. These results indicate that although TRPV3 channel activators were effective in increasing cytoplasmic Ca2+ concentration of differentiated human podocytes, their application is likely to evoke several off‐target effects and the contribution of TRPV3 channels to these Ca2+ responses is minimal.
Discussion
In our current study, we provided the first evidence for the functional expression of the heat‐sensitive members of the vanilloid subfamily of TRP channels in human podocytes. We described heat‐evoked Ca2+ signals and detected the presence of TRPV1, 2, 3 and 4 proteins in the conditionally immortalized human podocyte cell line we have investigated. However, native TRPV3 and TRPV4 channels were detected at lower molecular weight in podocytes compared to the recombinant channels, which might suggest different degradation of these channels in the two cell lines. Quantitative analysis of the mRNA transcripts revealed that TRPV1 and TRPV4 are the dominantly expressed TRPV channels, but TRPV2 and TRPV3 channels were also detected at lower levels. These findings are highly consistent with publicly available microarray data of Da Sacco et al. (2013) (GEO Series accession number: GSE49439). Moreover, an additional transcriptome analysis (Boerries et al., 2013) also detected TRPV1–4 transcripts in primary isolated mouse podocytes.
Dissecting the function of TRPV channels, we surprisingly found that the TRPV1‐specific agonist capsaicin and the ultrapotent agonist resiniferatoxin failed to induce significant Ca2+ entry to podocytes suggesting loss of vanilloid sensitivity or an impaired function of TRPV1 channels in the investigated cell line. TRPV1 channels, earlier identified as the capsaicin receptors, are robustly activated by capsaicin in human and rodents. However, TRPV1 channels have been found to be insensitive to capsaicin in several other species (Jordt and Julius, 2002; Gavva et al., 2004). Recent research revealed the molecular mechanism of capsaicin binding to TRPV1 channels and identified key amino acid residues, mutations of which decreased capsaicin sensitivity (Yang et al., 2015). Single nucleotide polymorphisms in the human TRPV1 protein are also known to be associated with lowered capsaicin sensitivity (Cantero‐Recasens et al., 2010). Moreover, a capsaicin‐insensitive splice variant TRPV1b has been identified, and its expression demonstrated in trigeminal and dorsal root ganglia (Lu et al., 2005; Charrua et al., 2008; Mistry et al., 2014) and in keratinocytes (Pecze et al., 2008). If TRPV1b is co‐expressed with TRPV1, it behaves as dominant negative subunit disrupting capsaicin/vanilloid sensitivity of the channel (Vos et al., 2006). In our case, both mutations in the key residues or the presence of the dominant negative subunit TRPV1b can be a rational explanation for the finding that in spite of the molecular expression of TRPV1 protein, we did not find any functional effect of capsaicin. Although desensitization by signalling pathways or functional inhibition by interacting partners, for example, phosphoinositols (Planells‐Cases et al., 2011; Rohacs, 2015), may also decrease the capsaicin sensitivity of TRPV1 channels, further studies are needed to identify the contribution of the different potential mechanisms.
In contrast to TRPV1, TRPV2 protein was detected not only at molecular level, but the presence of functional TRPV2 channels in the membrane of cultured human podocytes is strongly supported by our results showing that the TRPV2 channel agonist CBD induced a calcium influx from the extracellular space which was inhibited by tranilast, a suggested antagonist of TRPV2 channels. However, the specific TRPV4 channel blocker HC067047 also effectively inhibited CBD‐induced Ca2+ entry. Therefore, we concluded that functional TRPV4 channels can also be involved in the effect of CBD. Indeed, the classical TRPV4 agonist 4α‐PDD and the ultrapotent agonist GSK1016790A induced a rapid and robust increase in cytoplasmic Ca2+ concentrations which was strongly inhibited in the presence of the antagonist HC067047. In podocytes, GSK1016790A also induced marked transmembrane currents with a voltage‐dependence characteristic for TRPV4 channels (Jin et al., 2011) and blocked by HC067047. These functional results suggest that, in good accordance with the molecular expression data, TRPV4 channels are the dominantly expressed thermosensitive TRPV channels in human podocytes.
In contrast to TRPV4, the functional presence of TRPV3 channels was less clearly demonstrable. Although we identified the presence of TRPV3 proteins, quantitative analysis of expression of TRPV3 transcripts suggested a relatively low expression level compared to TRPV4. The pharmacological identification is uncertain since we lack commercially available, effective and highly specific TRPV3 channel agonists and antagonists. The botanical compounds carvacrol, thymol and eugenol, as well as the synthetic 2‐APB used in our experiments, are potent but highly non‐specific agonists, generally used to study TRPV3 channel functions (Chung et al., 2004; Xu et al., 2006; Vriens et al., 2008, 2009). In human podocytes, all these compounds evoked marked elevation of the cytoplasmic Ca2+ concentration, mainly derived from the extracellular space (at least if compounds were applied at concentrations ≤1 mM), but only the effect of 2‐APB reached a maximum over the concentration range applied, making possible the correct fitting of a sigmoidal dose–response curve. The experimentally determined EC50 (~500 μM) was higher than found earlier in electrophysiological studies on recombinant TRPV3 channels (~42 μM at physiological membrane potential; Chung et al., 2004). Moreover, the non‐selective TRP channel blocker, ruthenium red (Alexander et al., 2015a), could only partly block the effect of the compounds, and the endogenous TRPV3 inhibitor IPP partly blocked only 2‐APB evoked Ca2+ signals. In contrast, RNAi‐mediated silencing of the molecular expression of TRPV3 protein did not alter the effects of the agonists. All these results argue for off‐target effects of the TRPV3 channel ligands which can include the activation of several other TRP channels, and numerous other targets involved in cellular Ca2+ handling, such as the IP3 receptors, ryanodine receptors, sarcoplasmic reticulum Ca2+‐ATPase or store operated Ca2+ entry mechanisms (Chung et al., 2004; Xu et al., 2006; Sárközi et al., 2007; Vriens et al., 2008, 2009; Hsu et al., 2011; Liang and Lu, 2012). Therefore, although our results suggest that TRPV3 channels are expressed in human podocytes, their function is not clear. The exact role of this channels in the Ca2+ signals evoked by its activators needs further investigations. However, more specific pharmacological tools are needed to validate our results and further dissect the potential role of TRPV3 channels in podocytes.
The expression of heat and mechanosensitive TRPV channels has been investigated in the lower urinary tract and in the kidney, ever since their cloning (Hayes et al., 2000; Strotmann et al., 2000; Kassmann et al., 2013). Although there is clear evidence for the role of TRPV1 channels in the control of lower urinary tract functions, its expression in urothelial cells is still under debate (see, Franken et al., 2014). The TRPV4 channel is more abundantly expressed in the non‐neural cells of the urinary tract. In the kidney, TRPV4 expression was found overall in the constitutively water impermeable segments of the nephron (thin and thick ascending limb, distal convoluted tubule) and in the collecting ducts, as well (Tian et al., 2004). Moreover, both TRPV1 and TRPV4 proteins were described to form functionally active channels in the endothelium of the renal vasculature (Chen et al., 2015).
Although there is expression of heat‐sensitive TRPV channels in the kidney, we lack a complete understanding of their functions in the different segments of the tubular epithelium, and we especially lack any data regarding podocytes. Although actually we do not have data about the physiological role of TRPV1–4 channels in regulating cellular functions of podocytes, it is well known that Ca2+ signalling related to other TRP channels, namely TRPC6 and TRPC5 channels, have a crucial impact on the biological functions of podocytes, influencing cytoskeletal rearrangements and consequently the physical characteristics of the slit diaphragm and the filtration barrier. Interestingly, TRPC5 and TRPC6 channels seem to oppositely regulate podocyte actin dynamics and cell motility via RhoA and Rac1 respectively (Tian et al., 2010; Schaldecker et al., 2013; Tian and Ishibe, 2016). Moreover, a recent study suggested that wild‐type TRPC6 channels, but not the mutant allele TRPC6‐N143S, originally described in a family with FSGS, showed intrinsic mechanosensitivity and responded to hypotonic challenges (Wilson and Dryer, 2014), suggesting a potential role of osmotic stimuli and consequent (TRP mediated) Ca2+ signals in the regulation of podocyte function.
In the renal tubular system, an important role in transmitting the effect of tubular flow and osmolarity is attributed to TRPV4 channels (Mamenko et al., 2015). These channels mediated flow‐induced increases in intracellular Ca2+ concentration in medullary thick ascending limbs (Cabral et al., 2015), and their role was revealed in hypotonic stimuli‐induced Ca2+ entry needed for regulatory volume decrease in renal cortical collecting duct cells (Galizia et al., 2012). Beyond osmosensation, the TRPV4 channel seems to play an emerging role in the formation of epithelial barrier in several tissues. In airway epithelium, sheer stress enhanced epithelial barrier function via serial activation of TRPV4 channels and voltage‐gated L‐type Ca2+ channels (Sidhaye et al., 2008). In epidermal keratinocytes of the skin, functionally active TRPV4 channels were found to interact with adherent junction proteins and actin cytoskeleton, enhancing cell–cell junction and tight barrier formation. In this process, TRPV4 channels contributed to the elevation of intracellular Ca2+ concentration resulting in small GTPase Rho activation and consequent actin rearrangement. Moreover, its pharmacological activation augmented tight junction development and barrier recovery (Sokabe et al., 2010; Kida et al., 2012; Akazawa et al., 2013). Most recently, TRPV4 channels were described in bladder urothelium and kidney collecting duct epithelium associating with adherent junctions directly interacting with junctional proteins, especially α‐catenin, an intracellular adherent junction protein connected to the actin cytoskeleton (Janssen et al., 2016). All these data further suggest a putative contribution of TRPV4 channels to the fine orchestration of Ca2+ homeostasis in podocytes regulating the filtration barrier.
As podocytes in the outermost layer of the glomeruli form the final barrier to protein loss, their injury is often associated with marked proteinuria syndromes (Somlo and Mundel, 2000). Distinct diseases, like diabetic nephropathy, hypertension, as well as inherited or drug‐induced podocytopathies, can result in disruption of the slit diaphragm leading to proteinuria (Mathieson, 2011). Although the detailed pathomechanism is still unknown, cytoskeletal disorganization as a consequence of the altered Ca2+ signalling can be an important step. Although the potential role of TRPV channels has not been investigated yet, numerous studies suggested the role of several elements of the cellular Ca2+ signalling pathways, such as those related to TRPC6 channels or angiotensin II receptors (Wieder and Greka, 2016). The activity of the TRPV channels, especially TRPV4, can be affected directly by the altered, disease‐associated physical environment like increased flow and shear stress or altered osmotic concentrations, as detailed above. However, TRPV4 channels can be modulated by intracellular signalling pathways by, among others, angiotensin II signalling (Shukla et al., 2010; Tajada et al., 2017) which is of particular importance in podocytes (Hoffmann et al., 2004). These potential integrative role of the TRPV(4) channels can make them especially appealing targets for future drug developments in various forms of podocyte‐associated diseases.
All in all, although further studies are needed to clarify the potential role of TRPV channels in podocyte (patho)physiology, detailed understanding of their pharmacological role in physiological and disease conditions might contribute to the development of future therapies of primary and secondary podocytopathies and related kidney diseases.
Author contributions
L.A., B.I.T. and B.K. designed and performed the experiments and collected and analysed the data. T.S.Z and T.B. designed and managed the research study. L.A., B.I.T. and T.B. wrote the paper which was carefully edited and reviewed by all other authors.
Conflict of interest
The authors declare no conflicts of interest.
Declaration of transparency and scientific rigour
This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organisations engaged with supporting research.
Supporting information
Acknowledgements
The presented work was supported through the New National Excellence Program of the Ministry of Human Capacities and by Hungarian research grants OTKA 76065, NKFI K_16 120187, NKFI K_16 120552, TÁMOP‐4.2.2.A‐11/1/KONV‐2012‐0045 and LP003‐2011/2015. B.I.T. is a recipient of the János Bolyai research scholarship of the Hungarian Academy of Sciences.
Ambrus, L. , Kelemen, B. , Szabó, T. , Bíró, T. , and Tóth, B. I. (2017) Human podocytes express functional thermosensitive TRPV channels. British Journal of Pharmacology, 174: 4493–4507. doi: 10.1111/bph.14052.
References
- Akazawa Y, Yuki T, Yoshida H, Sugiyama Y, Inoue S (2013). Activation of TRPV4 strengthens the tight‐junction barrier in human epidermal keratinocytes. Skin Pharmacol Physiol 26: 15–21. [DOI] [PubMed] [Google Scholar]
- Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE et al (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Voltage‐gated ion channels. Br J Pharmacol 172: 5904–5941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Ligand‐gated ion channels. Br J Pharmacol 172: 5870–5903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alvarez DF, King JA, Weber D, Addison E, Liedtke W, Townsley MI (2006). Transient receptor potential vanilloid 4–mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res 99: 988–995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ambrus L, Oláh A, Oláh T, Balla G, Saleem MA, Orosz P et al (2015). Inhibition of TRPC6 by protein kinase C isoforms in cultured human podocytes. J Cell Mol Med 19: 2771–2779. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bang S, Yoo S, Yang T‐J, Cho H, Hwang SW (2011). Isopentenyl pyrophosphate is a novel antinociceptive substance that inhibits TRPV3 and TRPA1 ion channels. Pain 152: 1156–1164. [DOI] [PubMed] [Google Scholar]
- Boerries M, Grahammer F, Eiselein S, Buck M, Meyer C, Goedel M et al (2013). Molecular fingerprinting of the podocyte reveals novel gene and protein regulatory networks. Kidney Int 83: 1052–1064. [DOI] [PubMed] [Google Scholar]
- Cabral PD, Capurro C, Garvin JL (2015). TRPV4 mediates flow‐induced increases in intracellular Ca in medullary thick ascending limbs. Acta Physiol (Oxf) 214: 319–328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cantero‐Recasens G, Gonzalez JR, Fandos C, Duran‐Tauleria E, Smit LAM, Kauffmann F et al (2010). Loss of function of transient receptor potential vanilloid 1 (TRPV1) genetic variant is associated with lower risk of active childhood asthma. J Biol Chem 285: 27532–27535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997). The capsaicin receptor: a heat‐activated ion channel in the pain pathway. Nature 389: 816–824. [DOI] [PubMed] [Google Scholar]
- Charrua A, Reguenga C, Paule CC, Nagy I, Cruz F, Avelino A (2008). Cystitis is associated with TRPV1b‐downregulation in rat dorsal root ganglia. Neuroreport 19: 1469–1472. [DOI] [PubMed] [Google Scholar]
- Chen L, Kaßmann M, Sendeski M, Tsvetkov D, Marko L, Michalick L et al (2015). Functional transient receptor potential vanilloid 1 and transient receptor potential vanilloid 4 channels along different segments of the renal vasculature. Acta Physiol (Oxf) 213: 481–491. [DOI] [PubMed] [Google Scholar]
- Chung M‐K, Lee H, Mizuno A, Suzuki M, Caterina MJ (2004). 2‐Aminoethoxydiphenyl borate activates and sensitizes the heat‐gated ion channel TRPV3. J Neurosci 24: 5177–5182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA et al (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Da Sacco S, Lemley KV, Sedrakyan S, Zanusso I, Petrosyan A, Peti‐Peterdi J et al (2013). A novel source of cultured podocytes. PLoS One 8: e81812. [DOI] [PMC free article] [PubMed] [Google Scholar]
- De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA et al (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 204: 255–266. [DOI] [PubMed] [Google Scholar]
- Dimke H, Hoenderop JGJ, Bindels RJM (2011). Molecular basis of epithelial Ca2+ and Mg2+ transport: insights from the TRP channel family. J Physiol 589: 1535–1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dryer SE, Reiser J (2010). TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. Am J Physiol Renal Physiol 299: F689–F701. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Earley S, Brayden JE (2015). Transient receptor potential channels in the vasculature. Physiol Rev 95: 645–690. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert JP et al (2010). Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide‐induced cystitis. Proc Natl Acad Sci U S A 107: 19084–19089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Feng N‐H, Lee H‐H, Shiang J‐C, Ma M‐C (2008). Transient receptor potential vanilloid type 1 channels act as mechanoreceptors and cause substance P release and sensory activation in rat kidneys. Am J Physiol Renal Physiol 294: F316–F325. [DOI] [PubMed] [Google Scholar]
- Franken J, Uvin P, De Ridder D, Voets T (2014). TRP channels in lower urinary tract dysfunction. Br J Pharmacol 171: 2537–2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galizia L, Pizzoni A, Fernandez J, Rivarola V, Capurro C, Ford P (2012). Functional interaction between AQP2 and TRPV4 in renal cells. J Cell Biochem 113: 580–589. [DOI] [PubMed] [Google Scholar]
- Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S et al (2004). Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 279: 20283–20295. [DOI] [PubMed] [Google Scholar]
- Grace MS, Baxter M, Dubuis E, Birrell MA, Belvisi MG (2014). Transient receptor potential (TRP) channels in the airway: role in airway disease. Br J Pharmacol 171: 2593–2607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayes P, Meadows HJ, Gunthorpe MJ, Harries MH, Duckworth DM, Cairns W et al (2000). Cloning and functional expression of a human orthologue of rat vanilloid receptor‐1. Pain 88: 205–215. [DOI] [PubMed] [Google Scholar]
- Hisanaga E, Nagasawa M, Ueki K, Kulkarni RN, Mori M, Kojima I (2009). Regulation of calcium‐permeable TRPV2 channel by insulin in pancreatic beta‐cells. Diabetes 58: 174–184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoffmann S, Podlich D, Hähnel B, Kriz W, Gretz N (2004). Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol JASN 15: 1475–1487. [DOI] [PubMed] [Google Scholar]
- Hsu S‐S, Lin K‐L, Chou C‐T, Chiang A‐J, Liang W‐Z, Chang H‐T et al (2011). Effect of thymol on Ca2+ homeostasis and viability in human glioblastoma cells. Eur J Pharmacol 670: 85–91. [DOI] [PubMed] [Google Scholar]
- Janssen DAW, Jansen CJF, Hafmans TG, Verhaegh GW, Hoenderop JG, Heesakkers JPFA et al (2016). TRPV4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier. Acta Physiol (Oxf) 218: 38–48. [DOI] [PubMed] [Google Scholar]
- Jin M, Wu Z, Chen L, Jaimes J, Collins D, Walters ET et al (2011). Determinants of TRPV4 activity following selective activation by small molecule agonist GSK1016790A. PloS One 6: e16713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jordt S‐E, Julius D (2002). Molecular basis for species‐specific sensitivity to ‘hot’ chili peppers. Cell 108: 421–430. [DOI] [PubMed] [Google Scholar]
- Kassmann M, Harteneck C, Zhu Z, Nürnberg B, Tepel M, Gollasch M (2013). Transient receptor potential vanilloid 1 (TRPV1), TRPV4, and the kidney. Acta Physiol (Oxf) 207: 546–564. [DOI] [PubMed] [Google Scholar]
- Kida N, Sokabe T, Kashio M, Haruna K, Mizuno Y, Suga Y et al (2012). Importance of transient receptor potential vanilloid 4 (TRPV4) in epidermal barrier function in human skin keratinocytes. Pflüg Arch Eur J Physiol 463: 715–725. [DOI] [PubMed] [Google Scholar]
- Liang WZ, Lu CH (2012). Carvacrol‐induced [Ca2+]i rise and apoptosis in human glioblastoma cells. Life Sci 90: 703–711. [DOI] [PubMed] [Google Scholar]
- Lu G, Henderson D, Liu L, Reinhart PH, Simon SA (2005). TRPV1b, a functional human vanilloid receptor splice variant. Mol Pharmacol 67: 1119–1127. [DOI] [PubMed] [Google Scholar]
- Mamenko M, Zaika O, Boukelmoune N, O'Neil RG, Pochynyuk O (2015). Deciphering physiological role of the mechanosensitive TRPV4 channel in the distal nephron. Am J Physiol Renal Physiol 308: F275–F286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mathieson PW (2011). The podocyte as a target for therapies – new and old. Nat Rev Nephrol 8: 52–56. [DOI] [PubMed] [Google Scholar]
- Mihara H, Boudaka A, Shibasaki K, Yamanaka A, Sugiyama T, Tominaga M (2010). Involvement of TRPV2 activation in intestinal movement through nitric oxide production in mice. J Neurosci 30: 16536–16544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mistry S, Paule CC, Varga A, Photiou A, Jenes A, Avelino A et al (2014). Prolonged exposure to bradykinin and prostaglandin E2 increases TRPV1 mRNA but does not alter TRPV1 and TRPV1b protein expression in cultured rat primary sensory neurons. Neurosci Lett 564: 89–93. [DOI] [PubMed] [Google Scholar]
- Moran MM, McAlexander MA, Bíró T, Szallasi A (2011). Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 10: 601–620. [DOI] [PubMed] [Google Scholar]
- Nie L, Oishi Y, Doi I, Shibata H, Kojima I (1997). Inhibition of proliferation of MCF‐7 breast cancer cells by a blocker of Ca(2+)‐permeable channel. Cell Calcium 22: 75–82. [DOI] [PubMed] [Google Scholar]
- Nilius B, Szallasi A (2014). Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev 66: 676–814. [DOI] [PubMed] [Google Scholar]
- Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G et al (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest 124: 3713–3724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pecze L, Szabó K, Széll M, Jósvay K, Kaszás K, Kúsz E et al (2008). Human keratinocytes are vanilloid resistant. PLoS One 3: e3419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perálvarez‐Marín A, Doñate‐Macian P, Gaudet R (2013). What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel? FEBS J 280: 5471–5487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Planells‐Cases R, Valente P, Ferrer‐Montiel A, Qin F, Szallasi A (2011). Complex regulation of TRPV1 and related thermo‐TRPs: implications for therapeutic intervention. Adv Exp Med Biol 704: 491–515. [DOI] [PubMed] [Google Scholar]
- Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28: 6231–6238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Retailleau K, Duprat F (2014). Polycystins and partners: proposed role in mechanosensitivity. J Physiol 592: 2453–2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rohacs T (2015). Phosphoinositide regulation of TRPV1 revisited. Pflüg Arch Eur J Physiol 467: 1851–1869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T et al (2002). A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol JASN 13: 630–638. [DOI] [PubMed] [Google Scholar]
- Sárközi S, Almássy J, Lukács B, Dobrosi N, Nagy G, Jóna I (2007). Effect of natural phenol derivatives on skeletal type sarcoplasmic reticulum Ca2+ ‐ATPase and ryanodine receptor. J Muscle Res Cell Motil 28: 167–174. [DOI] [PubMed] [Google Scholar]
- Schaldecker T, Kim S, Tarabanis C, Tian D, Hakroush S, Castonguay P et al (2013). Inhibition of the TRPC5 ion channel protects the kidney filter. J Clin Invest 123: 5298–5309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schindelin J, Arganda‐Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012). Fiji: an open‐source platform for biological‐image analysis. Nat Methods 9: 676–682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schindelin J, Rueden CT, Hiner MC, Eliceiri KW (2015). The ImageJ ecosystem: an open platform for biomedical image analysis. Mol Reprod Dev 82: 518–529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shukla AK, Kim J, Ahn S, Xiao K, Shenoy SK, Liedtke W et al (2010). Arresting a transient receptor potential (TRP) channel: beta‐arrestin 1 mediates ubiquitination and functional down‐regulation of TRPV4. J Biol Chem 285: 30115–30125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sidhaye VK, Schweitzer KS, Caterina MJ, Shimoda L, King LS (2008). Shear stress regulates aquaporin‐5 and airway epithelial barrier function. Proc Natl Acad Sci U S A 105: 3345–3350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sokabe T, Fukumi‐Tominaga T, Yonemura S, Mizuno A, Tominaga M (2010). The TRPV4 channel contributes to intercellular junction formation in keratinocytes. J Biol Chem 285: 18749–18758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Somlo S, Mundel P (2000). Getting a foothold in nephrotic syndrome. Nat Genet 24: 333–335. [DOI] [PubMed] [Google Scholar]
- Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strotmann R, Harteneck C, Nunnenmacher K, Schultz G, Plant TD (2000). OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol 2: 695–702. [DOI] [PubMed] [Google Scholar]
- Tajada S, Moreno CM, O'Dwyer S, Woods S, Sato D, Navedo MF et al (2017). Distance constraints on activation of TRPV4 channels by AKAP150‐bound PKCα in arterial myocytes. J Gen Physiol 149: 639–659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP et al (2008). N‐((1S)‐1‐{[4‐((2S)‐2‐{[(2,4‐dichlorophenyl)sulfonyl]amino}‐3‐hydroxypropanoyl)‐1‐piperazinyl]carbonyl}‐3‐methylbutyl)‐1‐benzothiophene‐2‐carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther 326: 432–442. [DOI] [PubMed] [Google Scholar]
- Tian D, Jacobo SMP, Billing D, Rozkalne A, Gage SD, Anagnostou T et al (2010). Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal 3: ra77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tian W, Salanova M, Xu H, Lindsley JN, Oyama TT, Anderson S et al (2004). Renal expression of osmotically responsive cation channel TRPV4 is restricted to water‐impermeant nephron segments. Am J Physiol Renal Physiol 287: F17–F24. [DOI] [PubMed] [Google Scholar]
- Tian X, Ishibe S (2016). Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease. Nephrol Dial Transplant 31: 1577–1583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tóth BI, Nilius B (2015). Chapter 2 – transient receptor potential dysfunctions in hereditary diseases: TRP channelopathies and beyond A2 – Szallasi, Arpad In: TRP Channels as Therapeutic Targets. Academic Press: Boston, pp. 13–33. [Google Scholar]
- Tóth BI, Oláh A, Szöllősi AG, Bíró T (2014). TRP channels in the skin. Br J Pharmacol 171: 2568–2581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vos MH, Neelands TR, McDonald HA, Choi W, Kroeger PE, Puttfarcken PS et al (2006). TRPV1b overexpression negatively regulates TRPV1 responsiveness to capsaicin, heat and low pH in HEK293 cells. J Neurochem 99: 1088–1102. [DOI] [PubMed] [Google Scholar]
- Vriens J, Appendino G, Nilius B (2009). Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 75: 1262–1279. [DOI] [PubMed] [Google Scholar]
- Vriens J, Nilius B, Vennekens R (2008). Herbal compounds and toxins modulating TRP channels. Curr Neuropharmacol 6: 79–96. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Watanabe H, Davis JB, Smart D, Jerman JC, Smith GD, Hayes P et al (2002). Activation of TRPV4 channels (hVRL‐2/mTRP12) by phorbol derivatives. J Biol Chem 277: 13569–13577. [DOI] [PubMed] [Google Scholar]
- Wieder N, Greka A (2016). Calcium, TRPC channels, and regulation of the actin cytoskeleton in podocytes: towards a future of targeted therapies. Pediatr Nephrol Berl Ger 31: 1047–1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilson C, Dryer SE (2014). A mutation in TRPC6 channels abolishes their activation by hypoosmotic stretch but does not affect activation by diacylglycerol or G protein signaling cascades. Am J Physiol Renal Physiol 306: F1018–F1025. [DOI] [PubMed] [Google Scholar]
- Woudenberg‐Vrenken TE, Bindels RJM, Hoenderop JGJ (2009). The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol 5: 441–449. [DOI] [PubMed] [Google Scholar]
- Xu H, Delling M, Jun JC, Clapham DE (2006). Oregano, thyme and clove‐derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci 9: 628–635. [DOI] [PubMed] [Google Scholar]
- Yang D, Luo Z, Ma S, Wong WT, Ma L, Zhong J et al (2010). Activation of TRPV1 by dietary capsaicin improves endothelium‐dependent vasorelaxation and prevents hypertension. Cell Metab 12: 130–141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yang F, Xiao X, Cheng W, Yang W, Yu P, Song Z et al (2015). Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nat Chem Biol 11: 518–524. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.